Options are Expensive, shorting is risky

The data is positive, but seems like an overreaction for a small and early stage trial. Watching the chart and will enter a short in the future, at what level is difficult to say. I like the gaps down, however it is more likely to bleed lower versus dramatically dropping. XBI is nearing all time highs, this is a high beta stock, so the correlation will not be great.